Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization

Canadian Journal of Ophthalmology

Volumn 47, Issue 3, 2012, Pages 269-274

  Mansour, Ahmad M ^a   Arevalo, J Fernando ^b,c   Fardeau, Christine ^d   Hrisomalos, Emily N ^e   Chan, Wai Man ^f   Lai, Timothy Y Y ^f   Ziemssen, Focke ^g,h   Ness, Thomas ⁱ   Sibai, Abla Mehio ^a   MacKensen, Friederike ^j   Wolf, Armin ^k   Hrisomalos, Nicholas ^e   Heiligenhaus, Arnd ^l   Spital, Georg ^l   Jo, Yukari ^m   Gomi, Fumi ^m   Ikuno, Yasushi ^m   Akesbi, Jad ⁿ   LeHoang, Phuc ^d   Adan, Alfredo ^o   Mahendradas, Padmamalini ^p   Khairallah, Moncef ^q   Guthoff, Rainer ^r   Ghandour, Blanche ^a   Küçükerdönmez, Cem ^s   Kurup, Shree K ^t   more..

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

^c Clinica Oftalmologica Centro   (Venezuela)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e INDIANA UNIVERSITY   (United States)

^f CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^g University of Los Andes   (Venezuela)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ UNIVERSITY OF FREIBURG   (Germany)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY OF DUISBURG ESSEN   (Germany)

^m OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

ⁿ CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

^o UNIVERSITY OF BARCELONA   (Spain)

^p Narayana Health City   (India)

^q FATTOUMA BOURGUIBA UNIVERSITY HOSPITAL   (Tunisia)

^r UNIVERSITY OF WÜRZBURG   (Germany)

^s BASKENT UNIVERSITY   (Turkey)

^t WAKE FOREST BAPTIST HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID;

ADOLESCENT; ADULT; AGED; ARTICLE; CASE STUDY; CHILD; CHORIORETINOPATHY; CHOROIDITIS; CONTROLLED STUDY; EPIRETINAL MEMBRANE; EXPERIMENTAL STUDY; EYE INFLAMMATION; FEMALE; FIBROSIS; HUMAN; INTRAOCULAR HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCULAR FIBROSIS; OCULAR HISTOPLASMOSIS; OPTICAL COHERENCE TOMOGRAPHY; OPTICAL RESOLUTION; OUTCOME ASSESSMENT; RETINA FOVEA; RETINA ISCHEMIA; RETINA TEAR; RETINA VASCULITIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TOXOPLASMOSIS; UVEITIS; VISUAL ACUITY; VOGT KOYANAGI SYNDROME;

EID: 84862285277     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.1016/j.jcjo.2012.03.042     Document Type: Article

References (31)

1. Akesbi J, Brousseaud FX, Adam R, et al. Intravitreal bevacizumab (Avastin) in idiopathic retinitis, vasculitis, aneurysms and neuroretinitis. Acta Ophthalmol. 2010;88:40-1.
2. Ben Yahia S, Carl P, Herbort CP, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. Int Ophthalmol. 2008;28:311-6.
3. ChanWM,Lai TY, Liu DT, et al. Intravitreal bevacizumab (Avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol. 2007;143:977-83.
4. Guthoff R, Goebel W. Intravitreal bevacizumab for choroidal neovascularization in toxoplasmosis. Acta Ophthalmologica. 2009;87:688-90.
5. Julián K, Terrada C, Fardeau C, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: longterm results. Acta Ophthalmol. 2011;89:179-84.
6. Küc¸ükerdönmez C, Akova YA, Yilmaz G. Intravitreal injection of bevacizumab in Eales disease. Ocul Immunol Inflamm. 2008;16:63-5. (Pubitemid 351480327)
7. Kurup S, Lew J, Byrnes G, et al. Therapeutic efficacy of intravitreal bevacizumab on posterior uveitis complicated by neovascularization. Acta Ophthalmologica. 2009;87:349-52.
8. Raffa L, Bawazeer A. Intravitreal bevacizumab injection in a 14-year-old Vogt-Koyanagi-Harada patient with choroidal neovascular membrane. Can J Ophthalmol. 2009;44:615-6.
9. Tran TH, Fardeau C, Terrada C, et al. Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol. 2008;246:1685-92.
10. Wu L, Evans T, Saravia M, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to Vogt-Koyanagi-Harada syndrome. Jpn J Ophthalmol. 2009;53:57-60.
11. Mansour AM, Arevalo JF, Ziemssen F, et al. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2009;148:310-6.
12. Mansour AM, Mackensen F, Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol. 2008;146: 410-6.
13. Adán A, Mateo C, Navarro R, et al. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina. 2007;27:1180-6. (Pubitemid 350211522)
14. Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Arch Ophthalmol. 2008;126:1152-6.
15. Doctor PP, Bhat P, Sayed R, et al. Intravitreal bevacizumab for uveitic choroidal neovascularization. Ocul Immunol Inflamm. 2009;17:118-26.
16. Ehrlich R, Ciulla TA, Maturi R, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular histoplasmosis syndrome. Retina. 2009;29:1418-23.
17. Fine HF, Zhitomirsky I, Freund KB, et al. Bevacizumab (avastin) and ranibizumab (lucentis) for choroidal neovascularization in multifocal choroiditis. Retina. 2009;29:8-12.
18. Kramer M, Axer-Siegel R, JaouniI T, et al. Bevacizumab for choroidal neovascularization related to inflammatory diseases. Retina. 2010;30: 938-44.
19. Kumar A, Sinha S. Rapid regression of disc and retinal neovascularization in a case of Eales disease after intravitreal bevacizumab. Can J Ophthalmol. 2007;42:335-6. (Pubitemid 46713702)
20. Lott MN, Schiffman JC, Davis JL. Bevacizumab in inflammatory eye disease. Am J Ophthalmol. 2009;148:711-7.
21. Menezo V, Cuthbertson F, Susan DM. Positive response to intravitreal ranibizumab in the treatment of choroidal neovascularization secondary to punctate inner choroidopathy. Retina. 2010;30:1400-4.
22. Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina. 2011; online Feb 24. [Epub ahead of print].
23. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol. 2008;145:875-8.
24. Vossmerbaeumer U, Spandau UHM, Baltz S, et al. Intravitreal bevacizumab for choroidal neovascularization secondary to punctate inner choroidopathy (letter). Acta Ophthalmologica. 86:292-4.
25. Kleiner RC, Ratner CM, Enger C, et al. Subfoveal neovascularization in the ocular histoplasmosis syndrome. A natural history study. Retina. 1988;8:225-9. (Pubitemid 19044626)
26. Brown J Jr, Folk JC, Reddy CV, et al. Visual prognosis of multifocal choroiditis, punctate inner choroidopathy, and the diffuse subretinal fibrosis syndrome. Ophthalmology. 1996;103:1100-5. (Pubitemid 26249561)
27. Perentes Y, Chan CC, Bovey E, et al. Massive vascular endothelium growth factor (VEGF) expression in Eales' disease. Klin Monatsbl Augenheilkd. 2002;219:311-4. (Pubitemid 34625244)
28. Guerin E, Sheridan C, Assheton D, et al. SDF1-alpha is associated with VEGFR-2 in human choroidal neovascularisation. Available at http://www. sciencedirect.com/science/journal/00262862. Microvascular Research 2008;75:302-7.
29. Maruotti N, Cantatore FP, Nico B, et al. Angiogenesis in vasculitides. Clin Exp Rheumatol. 2008;26:476-83. (Pubitemid 352003221)
30. Murugeswari P, Shukla D, Rajendran A, et al. Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and Eales' disease. Retina. 2008; 28:817-24.
31. Shimada H, Yuzawa M, Hirose T, et al. Pathological findings of multifocal choroiditis with panuveitis and punctate inner choroidopathy. Jpn J Ophthalmol. 2008;52:282-8.